为了解黄芩的研究现状、研究热点，为后续的研究提供直观的数据参考依据和相关建议，检索2000年1月1日—2022年6月30日万方数据库（Wanfang Data）、中国学术期刊全文数据库（CNKI）、维普生物医学数据库（VIP）、中国生物医学文献数据库（CBM）、Web of Science（WOS）数据库以及PubMed医学文献检索服务系统中关于黄芩的文献，通过VOS viewer软件呈现可视化图谱进行文献计量分析。结果显示，22年来黄芩发文量呈波动上升趋势；中英文关键词聚类分析显示，目前对黄芩的研究以化学成分、药理作用、临床应用为主；关键词叠加时间可视化图谱显示黄芩-黄连药对治疗2型糖尿病、黄芩治疗新型冠状病毒肺炎（COVID-19）是有关黄芩的研究前沿内容；网络药理学与分子对接技术是探究药效物质基础的新方法。

In order to understand the research status and research hotspots of Scutellariae Radix, and provide intuitive data reference and related suggestions for subsequent research, the literature on Scutellariae Radix in Wanfang Database (Wanfang Data), China Academic Journal Full-text Database (CNKI), VIP Biomedical Database (VIP), China Biomedical Literature Database (CBM), Web of Science (WOS) database and PubMed medical literature retrieval service system from January 1, 2000 to June 30, 2022 were searched. Bibliometric analysis was performed by presenting a visual map through VOS viewer software. The results showed that the number of published articles of Scutellariae Radix increased with fluctuation in 22 years. Cluster analysis of Chinese and English keywords showed that the current research on Scutellariae Radix was mainly based on chemical composition, pharmacological action and clinical application. The visualization map of keyword superposition time showed that the treatment of type 2 diabetes mellitus by Scutellariae Radix-Coptidis Rhizoma drug pair and the treatment of novel coronavirus pneumonia (COVID-19) by Scutellariae Radix were the research frontiers of Scutellariae Radix. Network pharmacology and molecular docking technology are new methods to explore the pharmacodynamic material basis.

中央引导地方科技发展资金资助项目（206Z2501G）；河北省重点研发计划项目（20372502D）